论文部分内容阅读
目的探讨强化瑞舒伐他汀治疗对经皮冠状动脉介入(PCI)术后对比剂肾病(CIN)的预防作用。方法 PCI手术患者182例均分为2组:A组PCI术前72h应用瑞舒伐他汀20mg(每晚睡前口服)强化治疗;B组给予瑞舒伐他汀10mg(每晚睡前口服)常规治疗。观察术前、术后24、72h的空腹血清肌酐(SCr)、血尿素氮(BUN)、肌酐清除率(Ccr)、高敏C反应蛋白(hs-CRP)变化,比较两组CIN的发生率。结果与术前比较,术后24、72h两组SCr、hs-CRP均明显升高(P<0.05),Ccr明显下降(P<0.05)。术后24h及72h,A组SCr、hs-CRP低于B组(P<0.05),A组Ccr高于B组(P<0.05)。A组CIN发生率低于B组(2.20%vs.8.79%)(P<0.05)。结论 PCI术前强化瑞舒伐他汀治疗可降低PCI术后CIN发生率。
Objective To investigate the preventive effect of intensive rosuvastatin on contrast nephropathy (CIN) after percutaneous coronary intervention (PCI). Methods A total of 182 patients undergoing PCI were divided into two groups: Group A received intensive therapy with rosuvastatin 20mg (orally before bedtime every night) 72h before PCI; Group B received rosuvastatin 10mg (orally every night before bedtime) routine treatment. The changes of fasting serum creatinine (SCr), blood urea nitrogen (BUN), creatinine clearance (Ccr) and high sensitivity C-reactive protein (hs-CRP) were observed before and 24 and 72 hours after operation. Results Compared with preoperative, the levels of SCr and hs-CRP in both groups increased significantly (P <0.05) and Ccr decreased significantly at 24 and 72 hours after operation (P <0.05). The levels of SCr and hs-CRP in group A were lower than those in group B at 24h and 72h (P <0.05). The Ccr in group A was higher than that in group B (P <0.05). The incidence of CIN in group A was lower than that in group B (2.20% vs.8.79%) (P <0.05). Conclusion Pretreatment with rosuvastatin can reduce the incidence of CIN after PCI.